NCT05662410View on ClinicalTrials.gov

Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 26, 2022

Primary Completion Date

May 24, 2024

Study Completion Date

May 26, 2024

Conditions
Pachychoroid Neovasculopathy
Interventions
DRUG

Three monthly injections of intravitreal aflibercept

Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.

Trial Locations (1)

150-034

Jae Hui Kim, Seoul

All Listed Sponsors
collaborator

Nune Eye Hospital, Seoul, Korea

OTHER

collaborator

HanGil Eye Hospital

OTHER

lead

Kim's Eye Hospital

OTHER